ClinicalTrials.gg
CompletedNCT03011333Updated Mar 2, 2026Results posted

Phase 2B Upper Extremity Nerve Block Study

A Phase 2 interventional study of HTX-011 and Bupivacaine HCl without epinephrine in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
21st of 364
243 · median 70
Started
2017
with 30 others
Phase 2
43 of 364
4 open now
Registered
102nd of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 21st largest by enrollment, is one of 31 that started in 2017, is one of 43 in phase 2, and was the 102nd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 2B, randomized, assessor-blind, active- and saline placebo-controlled, multicenter study in subjects undergoing augmentation mammoplasty to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 when administered via ultrasound-guided lateral and medial pectoral nerve block before surgery.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants with a volume of 300 to 500 cc, inclusive. Note: textured implants are not allowed.
  • Has an Physical Status of I, II, or III.
  • Subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Has a planned concurrent surgical procedure.
  • Has a planned reconstructive procedure status post breast cancer therapy.
  • Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medication.
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken NSAIDs within 10 days prior to scheduled surgery.
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery other than to treat an AE that occurs after signing the ICF or for pretreatment prior to a needle placement.
  • Has initiated treatment with any of the following medications within 1 month prior to study drug administration or is taking any of these medications to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 (COX-2) inhibitors. (Note: If a subject is taking one of these medications for a reason other than pain control, she must be on a stable scheduled dose [ie, not "as needed"] for at least 1 month prior to study drug administration.) Anxiolytics prior to surgery are permitted, if necessary.
  • Has a medical condition that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Has a known history of , , or (HIV).
  • Has uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments
  • Has any chronic neuromuscular deficit of either pectoral nerve function or arm/shoulder/truncal musculature.
  • Has any chronic condition or disease that would compromise neurological or vascular assessments.
  • Had a in the last year, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half lives.
  • Has undergone 3 or more surgeries in 12 months.
  • Has a (BMI) >35 kg/m2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Group 1: HTX-011

    HTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.

    Drug: HTX-011

  • Experimental
    Group 2: HTX-011

    HTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.

    Drug: HTX-011

  • Experimental
    Group 3: HTX-011

    HTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.

    Drug: HTX-011

  • Experimental
    Group 4: HTX-011

    HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.

    Drug: HTX-011

  • Experimental
    Group 5: HTX-011

    HTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.

    Drug: HTX-011

  • Active comparator
    Group 6: Bupivacaine HCl

    Bupivacaine HCl without epinephrine, 50 mg via nerve block.

    Drug: Bupivacaine HCl without epinephrine

  • Placebo comparator
    Group 7: Saline Placebo

    Saline placebo via nerve block.

    Drug: Saline Placebo

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.

  • DrugBupivacaine HCl without epinephrine

    Bupivacaine HCl without epinephrine, 50 mg via nerve block.

  • DrugSaline Placebo

    Saline placebo via nerve block.

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24).

    Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-24 is 0-240. The prescribed activity for NRS-A is keeping the elbows at the side and against the body and then raising both hands in front of the abdomen with hands clasped and holding that position for at least 5 seconds.

    Time frame: 24 hours

Secondary outcomes

  1. Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)

    Time frame: 72 Hours

07

Results

Posted Oct 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline Placebo
Started12272547504141
Completed12262546463736
Not completed0101445
Withdrew: Lost to follow-up0101445

Outcome measures

PrimaryMean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24).

Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-24 is 0-240. The prescribed activity for NRS-A is keeping the elbows at the side and against the body and then raising both hands in front of the abdomen with hands clasped and holding that position for at least 5 seconds.

Time frame:
24 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24).
pain intensity score*hrGroup 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline Placebo
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24).124.51 ± 59.462136.17 ± 58.598136.76 ± 56.034116.71 ± 52.622114.87 ± 48.214133.83 ± 49.493151.52 ± 46.213
SecondaryMean Total Postoperative Opioid Consumption (in Morphine Equivalents)
Time frame:
72 Hours
Reported as:
Mean · Morphine milligram equivalents (MME)
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)
Morphine milligram equivalents (MME)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline Placebo
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)38.71 ± 28.65024.39 ± 19.87838.00 ± 19.45228.84 ± 22.60337.46 ± 21.45233.57 ± 23.08836.38 ± 23.275

Adverse events

Collected over 28 Days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: HTX-0110/12 (0%)0/12 (0%)11/12 (91.7%)
Group 2: HTX-0110/27 (0%)0/27 (0%)21/27 (77.8%)
Group 3: HTX-0110/25 (0%)1/25 (4%)23/25 (92%)
Group 4: HTX-0110/47 (0%)0/47 (0%)43/47 (91.5%)
Group 5: HTX-0110/50 (0%)1/50 (2%)47/50 (94%)
Group 6: Bupivacaine HCl0/41 (0%)2/41 (4.9%)33/41 (80.5%)
Group 7: Saline Placebo0/41 (0%)0/41 (0%)35/41 (85.4%)
Most frequent serious events
Most frequent serious events
EventGroup 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline Placebo
Breast haematomaReproductive system and breast disorders0/120/270/250/470/502/410/41
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/120/271/250/470/500/410/41
Device breakageProduct Issues0/120/270/250/471/500/410/41
Most frequent other events
Showing 10 of 23
Most frequent other events
EventGroup 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline Placebo
NauseaGastrointestinal disorders8/1215/2714/2537/4737/5025/4126/41
DizzinessNervous system disorders1/126/2710/254/476/508/414/41
VomitingGastrointestinal disorders4/126/277/2517/4719/5014/4116/41
PruritusSkin and subcutaneous tissue disorders4/121/274/252/474/507/415/41
Pruritus generalisedSkin and subcutaneous tissue disorders1/126/271/253/471/501/411/41
DysgeusiaNervous system disorders0/120/275/255/472/501/412/41
ConstipationGastrointestinal disorders2/124/272/257/477/506/418/41
HeadacheNervous system disorders0/124/274/253/477/504/415/41
Muscle twitchingMusculoskeletal and connective tissue disorders0/120/274/252/470/502/410/41
HyperhidrosisSkin and subcutaneous tissue disorders0/124/270/250/474/503/411/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
<=18 years00000000
Between 18 and 65 years12272547504141243
>=65 years00000000
Age, Continuous
Age, Continuous(Years)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
Mean31.4 ± 6.5632.1 ± 8.5130.5 ± 5.6430.9 ± 8.0832.0 ± 8.6430.4 ± 7.7531.3 ± 9.0331.2 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
Female12272547504141243
Male00000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
Hispanic or Latino610101817171694
Not Hispanic or Latino6171529332425149
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
American Indian or Alaska Native00000000
Asian011322211
Native Hawaiian or Other Pacific Islander00000000
Black or African American2436113736
White10222038373532194
More than one race00100102
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)Group 1: HTX-011Group 2: HTX-011Group 3: HTX-011Group 4: HTX-011Group 5: HTX-011Group 6: Bupivacaine HClGroup 7: Saline PlaceboTotal
United States12272547504141243
08

Study locations

2 sites
  • Pasadena, California 91105, United States
  • Houston, Texas 77027, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2018, 12 months.

Results were first posted in Oct 2021, 3 years 8 months after primary completion. A results delay was requested in Jun 2018.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 12 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 5, 2017
StartActual
Jan 14, 2017
Primary completionActual
Feb 1, 2018
CompletionActual
Mar 19, 2018
Results delay requested
Jun 8, 2018
Results first posted
Oct 29, 2021
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03011333
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Jan 14, 2017
Primary completion
Feb 1, 2018
Completion
Mar 19, 2018
Results posted
Oct 29, 2021
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion